Dyne Therapeutics, Inc. (DYN) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Dilution Analysis

Medium Risk

Moderate dilution risk

Last updated: May 11, 2026

Risk Assessment Details

Potential Dilution: 13.33% of current shares

Recent Dilution: 54.22% (2 years)

Historical Dilution Factor: significant recent dilution

Outstanding Shares

170M

Potential Supply

22M

Additional shares possible

Splits

None

Past 2 years

Summary

DYN currently has 165M outstanding shares. with limited dilution risk as only 22M additional shares (13.3%) are authorized for issuance. The company has significantly diluted shareholders by 54.22% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding	Supply
May 11, 2026	10-Q filing \| 165.2M shares outstanding	170M	22M
Nov 05, 2025	10-Q filing \| 142.8M shares outstanding	140M	22M
Jul 28, 2025	10-Q filing \| 142.3M shares outstanding	140M	22M
May 08, 2025	10-Q filing \| 113.7M shares outstanding	110M	22M
Feb 27, 2025	10-K filing \| 113.1M shares outstanding	110M	22M
Nov 12, 2024	10-Q filing \| 101.8M shares outstanding	100M	22M
Aug 12, 2024	10-Q filing \| 100.4M shares outstanding	100M	22M
May 02, 2024	10-Q filing \| 87.4M shares outstanding	87M	22M
Mar 05, 2024	10-K filing \| 82.0M shares outstanding	82M	22M
Oct 30, 2023	10-Q filing \| 61.4M shares outstanding	61M	22M
Aug 03, 2023	10-Q filing \| 61.0M shares outstanding	61M	22M
May 11, 2023	10-Q filing \| 58.3M shares outstanding	58M	22M
Mar 02, 2023	10-K filing \| 56.3M shares outstanding	56M	22M
Nov 03, 2022	10-Q filing \| 52.1M shares outstanding	52M	22M
Aug 04, 2022	10-Q filing \| 51.8M shares outstanding	52M	22M
May 02, 2022	10-Q filing \| 51.7M shares outstanding	52M	22M
Mar 10, 2022	10-K filing \| 51.6M shares outstanding	52M	22M
Nov 04, 2021	S-3 filing: The company is filing an S-3 to offer debt securities, common stock, and preferred stock from time to time in one or more offerings up to $400,000,000 in aggregate offering price.	52M	22M
Nov 04, 2021	10-Q filing \| 51.5M shares outstanding	52M	22M
Aug 05, 2021	10-Q filing \| 51.3M shares outstanding	51M	12M
May 06, 2021	10-Q filing \| 51.2M shares outstanding	51M	12M
Mar 04, 2021	10-K filing \| 51.5M shares outstanding	51M	12M
Jan 19, 2021	S-1 filing: This S-1 filing indicates an offering of 5,500,000 shares of common stock with an option to purchase an additional 825,000 shares. The company intends to use the proceeds for research and development, platform development, and working capital.	45M	12M
Nov 05, 2020	10-Q filing \| 45.4M shares outstanding	45M	0
Sep 10, 2020	S-1/A filing: This is an S-1/A filing for an initial public offering of common stock. J.P. Morgan, Jefferies, Piper Sandler, and Stifel are the joint book-running managers.	N/A	0
Aug 25, 2020	S-1 filing: This is an S-1 filing for an initial public offering of common stock, with J.P. Morgan Securities LLC and Jefferies LLC acting as joint book-running managers. The company intends to list its common stock on the Nasdaq Global Market under the symbol "DYN."	N/A	0

Back to DYN Details